$4.49
7.80% yesterday
Nasdaq, Nov 15, 10:17 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$4.49
+0.79 21.35% 1M
-3.61 44.57% 6M
-0.53 10.56% YTD
+0.40 9.78% 1Y
-2.65 37.11% 3Y
+3.39 308.18% 5Y
-30.15 87.04% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.38 7.80%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $3.13b
Enterprise Value $4.02b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 548.17
P/S ratio (TTM) P/S ratio 426.84
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,218.71%
Revenue (TTM) Revenue $7.33m
EBIT (operating result TTM) EBIT $-359.29m
Free Cash Flow (TTM) Free Cash Flow $-434.10m
Cash position $130.37m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 332.70
EV/Sales forward 419.93
Short interest 32.69%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a ImmunityBio Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a ImmunityBio Inc forecast:

Buy
67%
Hold
33%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.33 7.33
1,209% 1,209%
100%
- Direct Costs 18 18
25% 25%
245%
-11 -11
55% 55%
-145%
- Selling and Administrative Expenses 126 126
55% 55%
1,722%
- Research and Development Expense 204 204
12% 12%
2,789%
-341 -341
1% 1%
-4,656%
- Depreciation and Amortization 18 18
25% 25%
245%
EBIT (Operating Income) EBIT -359 -359
0% 0%
-4,902%
Net Profit -588 -588
28% 28%
-8,019%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
4 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025. ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercial and government...
Neutral
GlobeNewsWire
16 days ago
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation ...
Positive
Seeking Alpha
19 days ago
ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Keytruda or Opdivo, showed promising results in phase 2b for NSCLC, leading to upcoming phase 3 studies. The company has around $130.1 million in cash, bolstered by a $100 million infusion, enough to ...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 628
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today